In vitro interactions of LytA, the major pneumococcal autolysin, with two bacteriophage lytic enzymes (Cpl-1 and Pal), cefotaxime and moxifloxacin against antibiotic-susceptible and -resistant Streptococcus pneumoniae strains

Journal of Antimicrobial Chemotherapy

Volumn 60, Issue 5, 2007, Pages 1159-1162

  Rodríguez Cerrato, Violeta ^a   García, Pedro ^b   del Prado, Gema ^a   García, Ernesto ^b   Gracia, Matilde ^b   Huelves, Lorena ^a   Ponte, Carmen ^a   López, Rubens ^b   Soriano, Francisco ^a  

^a Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^b CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

Author keywords

Drug resistance; Enzybiotics; Killing curves; Lytic enzymes; Pneumococcus

Indexed keywords

AUTOLYSIN; CEFOTAXIME; HYDROLASE; HYDROLASE CPL 1; HYDROLASE PAL; MOXIFLOXACIN; PROTEIN LYTA; QUINOLINE DERIVED ANTIINFECTIVE AGENT; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL COUNT; BACTERIAL STRAIN; BACTERIOPHAGE; BACTERIUM COLONY; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STREPTOCOCCUS PNEUMONIAE;

ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; BACTERIAL PROTEINS; CEFOTAXIME; DRUG INTERACTIONS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; MICROBIAL SENSITIVITY TESTS; PROTEIN BINDING; QUINOLINES; STREPTOCOCCUS PHAGES; STREPTOCOCCUS PNEUMONIAE; VIRAL PROTEINS;

EID: 35448950078     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm342     Document Type: Article

References (10)

1. López R, García E, García P. Enzymes for anti-infective therapy: Phage lysins. Drug Discov Today: Therap Strat 2004; 1 469-74.
2. Fischetti VA. Bacteriophage lytic enzymes: Novel anti-infectives. Trends Microbiol 2005; 13: 491-6.
3. Djurkovic S, Loeffler JM, Fischetti VA. Synergistic killing of Streptococcus pneumoniae with the bacteriophage lytic enzyme Cpl-1 and penicillin or gentamicin depends on the level of penicillin resistance. Antimicrob Agents Chemother 2005; 49: 1225-8.
4. López R, García E. Recent trends on the molecular biology of pneumococcal capsules, lytic enzymes, and bacteriophage. FEMS Microbiol Rev 2004; 28: 553-80.
5. Jado I, López R, García E et al. Phade lytic enzymes as therapy of antibiotic-resistant Streptococcus pneumoniae infection in a murine sepsis model. J Antimicrob Chemother 2003; 52: 967-73.
6. Entenza JM, Loeffler JM, Grandgirard D et al. Therapeutic effects of bacteriophage Cpl-1 lysin against Streptococcus pneumoniae endocarditis in rats. Antimicrob Agents Chemother 2005; 49: 4789-92.
7. McGullers JA, Karlström Å, Iverson AR et al. Novel strategy to prevent otitis media caused by colonizing Streptococcus pneumoniae. PLoS Pathog. 2007; 3: E28.
8. Sánchez-Puelles JM, Sanz JM, García JL et al. Immobilization and single-step purification of fusion proteins using DEAE-cellulose. Eur J Biochem 1992; 203: 153-9.
9. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically - Seven Edition: Approved Standard M7-A2. CLSI, Wayne, PA, USA, 2006.
10. Eliopoulos G, Moellering RCJ. Antimicrobial combinations. In: Lorian V, ed. Antibiotics in Laboratory Medicine. Baltimore: The Williams & Wilkins Co., 1996; 330-96.